Skip to main content
Premium Trial:

Request an Annual Quote

Genoox Raises $6M in New Funding

NEW YORK (GenomeWeb) – Genomic analysis startup Genoox announced today that it has raised $6 million in a new funding round.

Genoox's next-generation sequencing technology employs machine learning algorithms to analyze large amounts of genetic data. The Tel Aviv, Israel-based company entered the US market in 2017 and raised $6 million in a Series A round last June.

The current financing round was led by Triventures, and also included Inimiti Capital and Glilot Capital Partners.

"As a doctor, having access to personalized medicine will transform how we provide care and empower us to deliver the right treatment at the right time," Triventures Cofounder and Managing Partner Peter Fitzgerald said in a statement. "The platform makes it simple and cost-effective to identify the genetic root causes of disease and medical issues, and has even identified new genetic variants that have enabled parents to save their children's lives." Fitzgerald has also joined Genoox's board.

In April, Genoox partnered with Bionano Genomics to develop a genome informatics workflow, which integrates Bionano's structural variant calls with sequencing data within the Genoox platform.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.